Well lots of information to digest so more than happy to be corrected. However at this time I minded towards what @Pledge maybe thinking. We had a conference call and at no point did anyone ask, what are the implications of missing the primary endpoint to this trial?
It seems that in some ways we are back to Heart. Great results but not the result we were aiming for. Long term this is going to be a great therapy option for CLBP, but right now is not the lift off news that we are waiting for. When digested this may put further pressure on the SP.
regards
Yelrom
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-114
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |